News & Media

    Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief Medical Officer

    Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the appointment of Bernard Schachtel, M.D. as Chief Medical Officer. Dr. Schachtel is the President and Medical Director of Schachtel Research Company (SRC), a contract research organization in Jupiter, FL.

    “It is an honor and a privilege to have Dr. Schachtel as Charleston’s Chief Medical Officer” said Paul Bosse, Chief Executive Officer of Charleston. “I am excited to be working with one of the best analgesic researchers in this industry. He brings wide experience to Charleston Laboratories and has designed unique, executable, and comprehensive drug development programs for our various analgesic drugs. In addition, Charleston will benefit greatly from Dr. Schachtel’s attention to detail, his scientific insights, and his expert management of clinical studies, which will help lead Charleston to the success he is accustomed to.”

    Dr. Schachtel brings to Charleston Laboratories over 30 years’ experience in analgesic research. A former member of the Board of Directors of the American Society of Clinical Pharmacology and Therapeutics, Dr. Schachtel has also served as Consultant to the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.

    Throughout his career Dr. Schachtel has also held academic appointments, including an Adjunct Professorship of Epidemiology and Biostatistics at McGill University and his current appointment at Yale University (Lecturer in Epidemiology and Public Health). He has also worked in the pharmaceutical industry (Procter & Gamble, Wyeth). Dr. Schachtel is currently located at SRC. All clinical studies for Charleston Laboratories will be overseen by SRC, known for its expertise in measuring patients’ symptoms (such as pain, headache, heartburn, nausea and vomiting), and its participation in multiple drug approvals in the US and worldwide.